ReviewInternational journal of clinical practice. Supplement2010
Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man.
Review in International journal of clinical practice. Supplement, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Association between uric acid and cardiac outcomes mediated by neutrophil-to-lymphocyte ratio in patients with left ventricular diastolic dysfunction and pulmonary hypertension.Scientific reports · 2024Article
- Blood Cholesterol and Triglycerides Associate with Right Ventricular Function in Pulmonary Hypertension.medRxiv : the preprint server for health sciences · 2024Article
- Metabolic pathways, genomic alterations, and post-translational modifications in pulmonary hypertension and cancer as therapeutic targets and biomarkers.Frontiers in pharmacology · 2024Article
- Metabolic Syndrome: A Narrative Review from the Oxidative Stress to the Management of Related Diseases.Antioxidants (Basel, Switzerland) · 2023Review
- Type 2 diabetes progression differently affects endothelial function and vascular contractility in the aorta and the pulmonary artery.Scientific reports · 2021Article
- Metabolic pathways associated with right ventricular adaptation to pulmonary hypertension: 3D analysis of cardiac magnetic resonance imaging.European heart journal. Cardiovascular Imaging · 2019Article
- Pulmonary vascular dysfunction in metabolic syndrome.The Journal of physiology · 2019Review
- Cell death-inducing DFF45-like effector C gene silencing alleviates pulmonary vascular remodeling in a type 2 diabetic rat model.Journal of diabetes investigation · 2018Article
- Metabolic reprogramming of the urea cycle pathway in experimental pulmonary arterial hypertension rats induced by monocrotaline.Respiratory research · 2018Article
- Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Cyp2c44 gene disruption exacerbated pulmonary hypertension and heart failure in female but not male mice.Pulmonary circulation · 2016Article
- The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension.PloS one · 2016Article
- Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.American journal of respiratory cell and molecular biology · 2013Article
- A potential role for insulin resistance in experimental pulmonary hypertension.The European respiratory journal · 2013Article
- A process-based review of mouse models of pulmonary hypertension.Pulmonary circulation · 2012Article
- Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension.Pulmonary circulationArticle
- Endoplasmic reticulum stress and pulmonary hypertension.Pulmonary circulationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Pulmonary arterial hypertension (PAH) is a complex disease with significant morbidity and mortality. Recent animal and human studies have highlighted abnormalities in regulation and metabolism of insulin, sex hormones, adipokines and lipids that may play a role in disease development. Mouse studies suggest features of the metabolic syndrome (MS) including insulin resistance, deficiencies in peroxisome proliferator-activated receptor γ and apolipoprotein E, and low adiponectin are linked to development of PAH. In humans, insulin resistance, the MS and low levels of high-density lipoprotein have been associated with PAH. In addition, abnormal metabolism of oestrogens has been demonstrated in human and animal models of PAH, suggesting an important relationship of sex hormones and pulmonary vascular disease. Improved understanding of how metabolic and hormonal derangements relate to development and progression of pulmonary hypertension may lead to better disease therapies and understanding of potential risk factors. This review will focus on the animal and human data regarding metabolic and sex hormone derangements in PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.